Absci Corporation
NASDAQ:ABSIBiotechnology
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
Volume 5.66M
Average 5.10M
ABSI Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Absci CorporationNASDAQ: ABSI
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $26.34M (cash outflow) rose 20.5% year over year, behind the +28.3% change in trailing-twelve-month free cash flow. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.
Context
- Free cash flow amounted to 3358.3% of revenue in FY2025, up 1752.5 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +20.5% toward the trailing-twelve-month pace of +28.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (94.03M) USD
- Year-over-year change
- -29.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (94.03M) | -29.2% |
| FY2024 | 2024-12-31 | (72.81M) | -11.2% |
| FY2023 | 2023-12-31 | (65.5M) | +32.8% |
| FY2022 | 2022-12-31 | (97.51M) | +1.1% |
| FY2021 | 2021-12-31 | (98.65M) | — |
Free Cash Flow vs competitors
How ABSI compares with its peers on the latest reported figures
- ABSI's LTM Mar 2026 free cash flow of $98.51M is the 2nd largest of the 3 companies compared; the peer median is $148.38M.
- Its year-over-year change of +28.3% is the 2nd highest of 3, against a peer median of +14.5%.
- Free cash flow amounts to 5365.2% of revenue for ABSI, versus a peer median of 388.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $204.13M | +68.4% | — | 640.1% |
| LTM Mar 2026 | $98.51M | +28.3% | -1.2% | 5365.2% | |
| LTM Sep 2026 | $92.64M | -39.5% | — | 136.5% | |
| Peer median (excluding ABSI) | $148.38M | +14.5% | — | 388.3% | |
Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.96M) | (104.9M) | (110.57M) | (103.11M) | (115.18M) |
| Depreciation & Amortization | 6.65M | 13.1M | 14M | 13.39M | 11.74M |
| Deferred Income Tax | (8.9M) | (505K) | (52K) | 0 | 0 |
| Stock-Based Compensation | 10.61M | 12.54M | 11.42M | 19.45M | 18.32M |
| Change in Working Capital | (3.15M) | (1.54M) | 1.52M | (368K) | 423K |
| Accounts Receivables | 230K | (148K) | (666K) | 2.24M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (533K) | (786K) | 2.03M | 1.09M |
| Other Working Capital | (4.95M) | (859K) | 2.97M | (4.63M) | (671K) |
| Other Non-Cash Items | 35.15M | (30K) | 19.05M | (1.77M) | (8.23M) |
| Operating Cash Flow | (60.6M) | (81.34M) | (64.64M) | (72.4M) | (92.93M) |
| Capital Expenditures | (38.05M) | (16.18M) | (860K) | (404K) | (1.11M) |
| Acquisitions (Net) | (28.13M) | (8M) | 0 | 0 | 1.31M |
| Purchases of Investments | (1.2M) | (108.59M) | (147.35M) | (186.11M) | (119.87M) |
| Sales of Investments | 0 | 5M | 229.9M | 144M | 69.5M |
| Other Investing Activities | 0 | 783K | 254K | 939K | 0 |
| Investing Cash Flow | (67.38M) | (126.98M) | 81.94M | (41.58M) | (50.16M) |
| Debt Repayment | 120.85M | 4.58M | (5.35M) | (4.03M) | (3.2M) |
| Common Stock Issued | 210.4M | 656K | 862K | 86.56M | 109.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 336.19M | 5.24M | (4.48M) | 82.53M | 105.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 208.22M | (203.08M) | 12.83M | (31.45M) | (37.14M) |
| Free Cash Flow | (98.65M) | (97.51M) | (65.5M) | (72.81M) | (94.03M) |
Absci Corporation
NASDAQ:ABSI
Intrinsic Alpha fair value
Locked
Current Price
$8.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.